Trial Profile

A Multicenter Open label Phase 2 study of Carfilzomib Weekly plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carfilzomib (Primary) ; Melphalan; Prednisone
Indications Multiple myeloma
Focus Adverse reactions

Most Recent Events

10 Dec 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology.
24 Jun 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jul 2021.
04 Jun 2019 Results assessing carfilzomib maintenance for 1 year in patients with newly diagnosed multiple myeloma, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com